Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 22140424)

1.

Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.

Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V; 16-Year Long-Term Follow-up Study Investigators.

PLoS One. 2011;6(11):e22444. doi: 10.1371/journal.pone.0022444. Epub 2011 Nov 30.

2.

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC; 16-Year Long Term Follow-up Study Investigators.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7. doi: 10.1136/jnnp-2011-301178. Epub 2011 Dec 21.

PMID:
22193561
3.

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group.

Lancet. 2007 Aug 4;370(9585):389-97.

PMID:
17679016
4.

Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.

Pan F, Goh JW, Cutter G, Su W, Pleimes D, Wang C.

Clin Ther. 2012 Sep;34(9):1966-76. doi: 10.1016/j.clinthera.2012.07.010. Epub 2012 Aug 18.

PMID:
22906738
5.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

6.

Interferon-β-1b: a review of its use in multiple sclerosis.

Plosker GL.

CNS Drugs. 2011 Jan;25(1):67-88. doi: 10.2165/11206430-000000000-00000. Review.

PMID:
21128695
7.

Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.

Carroll WM.

Mult Scler. 2009 Aug;15(8):951-8. doi: 10.1177/1352458509105426. Epub 2009 May 22. Review.

PMID:
19465446
8.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
9.

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.

Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, Gray R.

BMJ. 2009 Dec 2;339:b4677. doi: 10.1136/bmj.b4677.

10.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
11.

Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.

Goodkin DE, Rudick RA, VanderBrug Medendorp S, Greene T, Schwetz KM, Fischer J, Daughtry MM, Ross J, Van Dyke C.

Online J Curr Clin Trials. 1992 Sep 25;Doc No 19:[7723 words; 89 paragraphs].

PMID:
1343611
12.
13.

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group.

Ann Neurol. 2009 Oct;66(4):513-20. doi: 10.1002/ana.21757.

PMID:
19847899
14.

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.

Kobelt G, Jönsson L, Miltenburger C, Jönsson B.

Int J Technol Assess Health Care. 2002 Winter;18(1):127-38.

PMID:
11987436
15.

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

Brown MG, Murray TJ, Sketris IS, Fisk JD, LeBlanc JC, Schwartz CE, Skedgel C.

Int J Technol Assess Health Care. 2000 Summer;16(3):751-67.

PMID:
11028131
16.

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.

Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators.

Arch Neurol. 2012 Feb;69(2):183-90. doi: 10.1001/archneurol.2011.1426. Epub 2011 Oct 10.

PMID:
21987393
17.

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.

Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2006 Dec;10(49):iii-iv, ix-xi, 1-157. Review.

18.

The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis.

Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, Granieri E, Rosati G, Savettieri G, Comi G, Livrea P; MSDN Study Group.

Mult Scler. 2006 Oct;12(5):578-85.

PMID:
17086903
19.

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Direnzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network Group.

J Neurol Sci. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16.

PMID:
19615696
20.

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2005 May;9(21):1-179, iii-iv. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk